174 related articles for article (PubMed ID: 12597983)
1. Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
Fechner G; Perabo FG; Schmidt DH; Haase L; Ludwig E; Schueller H; Blatter J; Mller SC; Albers P
Urology; 2003 Feb; 61(2):468-73. PubMed ID: 12597983
[TBL] [Abstract][Full Text] [Related]
2. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
[TBL] [Abstract][Full Text] [Related]
3. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Kielb SJ; Shah NL; Rubin MA; Sanda MG
J Urol; 2001 Aug; 166(2):482-7. PubMed ID: 11458051
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
da Silva GN; de Castro Marcondes JP; de Camargo EA; da Silva Passos Júnior GA; Sakamoto-Hojo ET; Salvadori DM
Exp Biol Med (Maywood); 2010 Jul; 235(7):814-24. PubMed ID: 20558835
[TBL] [Abstract][Full Text] [Related]
5. Hyperoxia-induced improvement of the in vitro response to gemcitabine in transitional cell carcinoma.
Fechner G; Dederichs F; Schmidt D; Müller S; Vaupel P; Albers P
Anticancer Res; 2005; 25(5):3413-8. PubMed ID: 16101157
[TBL] [Abstract][Full Text] [Related]
6. [The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine].
Mose S; Karapetian M; Jüling-Pohlit L; Taborski B; Ramm U; Damrau M; Rahn A; Böttcher HD
Strahlenther Onkol; 1999 Feb; 175(2):78-83. PubMed ID: 10065143
[TBL] [Abstract][Full Text] [Related]
7. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Takeuchi H; Mmeje CO; Jinesh GG; Taoka R; Kamat AM
Oncol Rep; 2015 Nov; 34(5):2738-44. PubMed ID: 26323344
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Sangar VK; McBain CA; Lyons J; Ramani VA; Logue JP; Wylie JP; Clarke NW; Cowan RA
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):420-5. PubMed ID: 15667962
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
10. The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Dyshlovoy SA; Madanchi R; Hauschild J; Otte K; Alsdorf WH; Schumacher U; Kalinin VI; Silchenko AS; Avilov SA; Honecker F; Stonik VA; Bokemeyer C; von Amsberg G
BMC Cancer; 2017 Feb; 17(1):93. PubMed ID: 28143426
[TBL] [Abstract][Full Text] [Related]
11. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Tolis C; Peters GJ; Ferreira CG; Pinedo HM; Giaccone G
Eur J Cancer; 1999 May; 35(5):796-807. PubMed ID: 10505042
[TBL] [Abstract][Full Text] [Related]
12. No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Camargo EA; da Silva GN; Gobette CP; Marcondes JP; Salvadori DM
Asian Pac J Cancer Prev; 2013; 14(10):5941-8. PubMed ID: 24289605
[TBL] [Abstract][Full Text] [Related]
13. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
Ostruszka LJ; Shewach DS
Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531
[TBL] [Abstract][Full Text] [Related]
14. Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.
Wouters A; Pauwels B; Lambrechts HA; Pattyn GG; Ides J; Baay M; Meijnders P; Peeters M; Vermorken JB; Lardon F
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):558-66. PubMed ID: 21377279
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.
Robinson BW; Shewach DS
Clin Cancer Res; 2001 Aug; 7(8):2581-9. PubMed ID: 11489842
[TBL] [Abstract][Full Text] [Related]
16. Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.
Salem SD; Abou-Tarboush FM; Saeed NM; Al-Qadasi WD; Farah MA; Al-Buhairi M; Al-Harbi N; Alhazza I; Alsbeih G
Gene; 2012 May; 498(2):300-7. PubMed ID: 22353361
[TBL] [Abstract][Full Text] [Related]
17. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Herman JM; Smith DC; Montie J; Hayman JA; Sullivan MA; Kent E; Griffith KA; Esper P; Sandler HM
Urology; 2004 Jul; 64(1):69-73. PubMed ID: 15245938
[TBL] [Abstract][Full Text] [Related]
18. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Gunelli R; Bercovich E; Nanni O; Ballardini M; Frassineti GL; Giovannini N; Fiori M; Pasquini E; Ulivi P; Pappagallo GL; Silvestrini R; Zoli W
Br J Cancer; 2007 Dec; 97(11):1499-504. PubMed ID: 17987035
[TBL] [Abstract][Full Text] [Related]
19. Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Mallick JA; Ali SA; Siddiqui N; Fareed A
J Pak Med Assoc; 2003 Nov; 53(11):547-52. PubMed ID: 14738263
[TBL] [Abstract][Full Text] [Related]
20. Radiation enhancement by gemcitabine-mediated cell cycle modulations.
Mose S; Class R; Weber HW; Rahn A; Brady LW; Böttcher HD
Am J Clin Oncol; 2003 Feb; 26(1):60-9. PubMed ID: 12576927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
